• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

芳基哌嗪 5-羟色胺能/多巴胺能配体的设计与合成及其神经保护特性。

Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties.

机构信息

Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy.

Institute of Pharmaceutical Chemistry, Goethe-University, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.

出版信息

Molecules. 2022 Feb 15;27(4):1297. doi: 10.3390/molecules27041297.

DOI:10.3390/molecules27041297
PMID:35209087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8877291/
Abstract

Long-chain arylpiperazine scaffold is a versatile template to design central nervous system (CNS) drugs that target serotonin and dopamine receptors. Here we describe the synthesis and biological evaluation of ten new arylpiperazine derivatives designed to obtain an affinity profile at serotonin 5-HT, 5-HT, 5-HT receptor, and dopamine D receptor of prospective drugs to treat the core symptoms of autism spectrum disorder (ASD) or psychosis. Besides the structural features required for affinity at the target receptors, the new compounds incorporated structural fragments with antioxidant properties to counteract oxidative stress connected with ASD and psychosis. All the new compounds showed CNS MultiParameter Optimization score predictive of desirable ADMET properties and cross the blood-brain barrier. We identified compound that combines an affinity profile compatible with antipsychotic activity (5-HT = 41.5 nM, 5-HT = 315 nM, 5-HT = 42.5 nM, D = 300 nM), and compound that has an affinity profile consistent with studies in the context of ASD (5-HT = 23.9 nM, 5-HT = 39.4 nM, 5-HT = 45.0 nM). Both compounds also had antioxidant properties. All compounds showed low in vitro metabolic stability, the only exception being compound , which might be suitable for studies in vivo.

摘要

长链芳基哌嗪骨架是设计靶向 5-羟色胺(5-HT)和多巴胺受体的中枢神经系统(CNS)药物的多功能模板。在这里,我们描述了十个新的芳基哌嗪衍生物的合成和生物学评价,这些衍生物旨在获得对治疗自闭症谱系障碍(ASD)或精神病核心症状的潜在药物的 5-HT 受体、5-HT 受体和多巴胺 D 受体的亲和力谱。除了目标受体亲和力所需的结构特征外,新化合物还包含具有抗氧化特性的结构片段,以抵消与 ASD 和精神病相关的氧化应激。所有新化合物均显示出 CNS 多参数优化评分,预示着理想的 ADMET 特性,并能穿越血脑屏障。我们鉴定出了一种具有抗精神病活性(5-HT = 41.5 nM,5-HT = 315 nM,5-HT = 42.5 nM,D = 300 nM)亲和力谱的化合物 ,以及一种具有与 ASD 背景下研究一致的亲和力谱的化合物 (5-HT = 23.9 nM,5-HT = 39.4 nM,5-HT = 45.0 nM)。这两种化合物都具有抗氧化特性。所有化合物在体外代谢稳定性都较低,唯一的例外是化合物 ,这可能适合体内研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/516f3fae5d76/molecules-27-01297-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/cd3c2e4cd402/molecules-27-01297-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/eaa43e461a21/molecules-27-01297-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/a01801b16f48/molecules-27-01297-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/312f2bcda4a2/molecules-27-01297-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/f67709c3f818/molecules-27-01297-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/516f3fae5d76/molecules-27-01297-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/cd3c2e4cd402/molecules-27-01297-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/eaa43e461a21/molecules-27-01297-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/a01801b16f48/molecules-27-01297-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/312f2bcda4a2/molecules-27-01297-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/f67709c3f818/molecules-27-01297-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6c67/8877291/516f3fae5d76/molecules-27-01297-g005.jpg

相似文献

1
Design and Synthesis of Arylpiperazine Serotonergic/Dopaminergic Ligands with Neuroprotective Properties.芳基哌嗪 5-羟色胺能/多巴胺能配体的设计与合成及其神经保护特性。
Molecules. 2022 Feb 15;27(4):1297. doi: 10.3390/molecules27041297.
2
New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors.新型芳基哌嗪烷基 8-烷氧基嘌呤-2,6-二酮和二氢[1,3]恶唑并[2,3-f]嘌呤-2,6-二酮衍生物,靶向 5-羟色胺 5-HT1A/5-HT2A/5-HT7 和多巴胺 D2 受体。
Arch Pharm (Weinheim). 2015 Apr;348(4):242-53. doi: 10.1002/ardp.201500015. Epub 2015 Mar 13.
3
Bioisosteric approach in the design of new dopaminergic/serotonergic ligands.新型多巴胺能/5-羟色胺能配体设计中的生物电子等排体方法
Curr Med Chem. 1998 Dec;5(6):493-512.
4
Design of novel dopamine D and serotonin 5-HT receptors dual antagonists toward schizophrenia: An integrated study with QSAR, molecular docking, virtual screening and molecular dynamics simulations.新型多巴胺 D 和血清素 5-HT 受体双重拮抗剂设计用于治疗精神分裂症:基于 QSAR、分子对接、虚拟筛选和分子动力学模拟的综合研究。
J Biomol Struct Dyn. 2020 Feb;38(3):860-885. doi: 10.1080/07391102.2019.1590244. Epub 2019 Mar 27.
5
The impact of the halogen bonding on D and 5-HT/5-HT receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties.卤素键对具有抗精神病和抗抑郁特性的4-[(2-乙基)哌啶基-1-基]苯基哌嗪的嗪磺酰胺的D和5-羟色胺/5-羟色胺受体活性的影响。
Bioorg Med Chem. 2017 Jul 15;25(14):3638-3648. doi: 10.1016/j.bmc.2017.04.046. Epub 2017 May 4.
6
Synthesis and in vitro pharmacological evaluation of novel 2-hydroxypropyl-4-arylpiperazine derivatives as serotoninergic ligands.新型2-羟丙基-4-芳基哌嗪衍生物作为5-羟色胺能配体的合成及体外药理学评价
Arch Pharm (Weinheim). 2014 Oct;347(10):698-706. doi: 10.1002/ardp.201400174. Epub 2014 Aug 11.
7
Neuroprotective arylpiperazine dopaminergic/serotonergic ligands suppress experimental autoimmune encephalomyelitis in rats.具有神经保护作用的芳基哌嗪多巴胺能/5-羟色胺能配体可抑制大鼠实验性自身免疫性脑脊髓炎。
J Neurochem. 2015 Oct;135(1):125-38. doi: 10.1111/jnc.13198. Epub 2015 Jul 15.
8
Design and synthesis of new potent 5-HT receptor ligands as a candidate for the treatment of central nervous system diseases.新型强效 5-HT 受体配体的设计与合成,作为治疗中枢神经系统疾病的候选药物。
Eur J Med Chem. 2022 Jan 5;227:113931. doi: 10.1016/j.ejmech.2021.113931. Epub 2021 Oct 21.
9
Towards the development of 5-HT₇ ligands combining serotonin-like and arylpiperazine moieties.朝着开发结合了血清素样和芳基哌嗪部分的 5-HT₇ 配体的方向发展。
Eur J Med Chem. 2014 Jun 10;80:8-35. doi: 10.1016/j.ejmech.2014.04.034. Epub 2014 Apr 13.
10
Design, synthesis and molecular modelling of new bulky Fananserin derivatives with altered pharmacological profile as potential antidepressants.新型大体积法喃色林衍生物的设计、合成与分子模拟及其作为潜在抗抑郁药的药理学特性改变。
Bioorg Med Chem. 2019 Aug 1;27(15):3396-3407. doi: 10.1016/j.bmc.2019.06.028. Epub 2019 Jun 21.

引用本文的文献

1
Structural Aspects of Arylpiperazines as Aminergic GPCR Ligands.作为胺能GPCR配体的芳基哌嗪的结构方面
Molecules. 2025 Jun 11;30(12):2545. doi: 10.3390/molecules30122545.
2
Discovery of a Novel, Potent, and Selective 5‑Hydroxytryptamine 2B Receptor Antagonist that Induces Mitochondrial Biogenesis in the Kidney.发现一种新型、强效且选择性的5-羟色胺2B受体拮抗剂,其可诱导肾脏中的线粒体生物合成。
ACS Pharmacol Transl Sci. 2025 May 30;8(6):1741-1755. doi: 10.1021/acsptsci.5c00161. eCollection 2025 Jun 13.

本文引用的文献

1
Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist.多巴胺 D1 受体与 G 蛋白和非儿茶酚胺激动剂复合物的晶体结构。
Nat Commun. 2021 Jun 3;12(1):3305. doi: 10.1038/s41467-021-23519-9.
2
Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder.基于知识的多靶点血清素受体靶向长链芳基哌嗪衍生物的设计:治疗自闭症谱系障碍的潜在候选药物。
ACS Chem Neurosci. 2021 Apr 21;12(8):1313-1327. doi: 10.1021/acschemneuro.0c00647. Epub 2021 Apr 1.
3
Structural insights into the lipid and ligand regulation of serotonin receptors.
解析血清素受体的脂质和配体调节的结构见解。
Nature. 2021 Apr;592(7854):469-473. doi: 10.1038/s41586-021-03376-8. Epub 2021 Mar 24.
4
U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.2015 年至 2020 年 6 月美国食品和药物管理局批准的药物:一个视角。
J Med Chem. 2021 Mar 11;64(5):2339-2381. doi: 10.1021/acs.jmedchem.0c01786. Epub 2021 Feb 22.
5
Structure of a Hallucinogen-Activated Gq-Coupled 5-HT Serotonin Receptor.致幻剂激活的 Gq 偶联 5-羟色胺受体的结构。
Cell. 2020 Sep 17;182(6):1574-1588.e19. doi: 10.1016/j.cell.2020.08.024.
6
Oxidative Stress and Immune System Dysfunction in Autism Spectrum Disorders.自闭症谱系障碍中的氧化应激和免疫系统功能障碍。
Int J Mol Sci. 2020 May 6;21(9):3293. doi: 10.3390/ijms21093293.
7
New thiazole, pyridine and pyrazole derivatives as antioxidant candidates: synthesis, DFT calculations and molecular docking study.新型噻唑、吡啶和吡唑衍生物作为抗氧化剂候选物:合成、密度泛函理论计算及分子对接研究
Heliyon. 2020 Jan 9;6(1):e03185. doi: 10.1016/j.heliyon.2020.e03185. eCollection 2020 Jan.
8
Lurasidone Sub-Chronically Activates Serotonergic Transmission via Desensitization of 5-HT1A and 5-HT7 Receptors in Dorsal Raphe Nucleus.鲁拉西酮通过使中缝背核中的5-HT1A和5-HT7受体脱敏而亚慢性激活5-羟色胺能传递。
Pharmaceuticals (Basel). 2019 Oct 6;12(4):149. doi: 10.3390/ph12040149.
9
Protective effect of 5-HT7 receptor activation against glutamate-induced neurotoxicity in human neuroblastoma SH-SY5Y cells via antioxidative and antiapoptotic pathways.5-HT7 受体激活通过抗氧化和抗细胞凋亡途径对谷氨酸诱导的人神经母细胞瘤 SH-SY5Y 细胞毒性的保护作用。
Neurotoxicol Teratol. 2019 Mar-Apr;72:22-28. doi: 10.1016/j.ntt.2019.01.002. Epub 2019 Jan 24.
10
Binding kinetics of cariprazine and aripiprazole at the dopamine D receptor.卡利拉嗪和阿立哌唑在多巴胺 D 受体的结合动力学。
Sci Rep. 2018 Aug 21;8(1):12509. doi: 10.1038/s41598-018-30794-y.